Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert C Bourge

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
American Heart Journal|August 23, 2006
Temporal trends and drug exposures in pulmonary hypertension: an American experienceAlexander M Walker, David Langleben, James J Korelitz, et al.
Pulmonary Circulation|May 6, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguatFranck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, et al.
Chest|June 7, 2017
Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation ProcedureAaron B Waxman, Hugh T McElderry, Mardi Gomberg-Maitland, et al.
Journal of the American College of Cardiology|June 6, 2006
Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failureMilton Packer, William T Abraham, Mandeep R Mehra, et al.
American Journal of Respiratory and Critical Care Medicine|December 14, 2021
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?Carmine Dario Vizza, Irene M Lang, Roberto Badagliacca, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
American Heart Journal|August 23, 2006
Temporal trends and drug exposures in pulmonary hypertension: an American experienceAlexander M Walker, David Langleben, James J Korelitz, et al.
Pulmonary Circulation|May 6, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguatFranck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, et al.
Chest|June 7, 2017
Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation ProcedureAaron B Waxman, Hugh T McElderry, Mardi Gomberg-Maitland, et al.
Journal of the American College of Cardiology|June 6, 2006
Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failureMilton Packer, William T Abraham, Mandeep R Mehra, et al.
American Journal of Respiratory and Critical Care Medicine|December 14, 2021
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?Carmine Dario Vizza, Irene M Lang, Roberto Badagliacca, et al.
Pageof 10